Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02329184 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
A Phase 1 study, sponsored by MyoKardia.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02329184 is a Phase 1 study that has completed, run by MyoKardia. The registered enrollment target is 15 participants.
The verdict
NCT02329184, a Phase 1 study, has completed, sponsored by MyoKardia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose study in NYHA Class I, II, or III patient volunteers aged 18-65 years.
Interventions
- DRUG MYK-461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02329184
The ClinicalTrials.gov registry entry for NCT02329184 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MyoKardia, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MYK-461 is the first listed.
NCT02329184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02329184 about?
NCT02329184 is a clinical study titled "Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461". The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose study in NYHA Class I, II, or III patient volunteers aged 18-65 years.
What is the current status of trial NCT02329184?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02329184?
The interventions under investigation include: MYK-461 (DRUG).
Who is sponsoring clinical trial NCT02329184?
This trial is sponsored by MyoKardia, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.